Last reviewed · How we verify
NCT04131426
Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia
Phase 1 trial testing Remune in Cachexia; Cancer in 25 participants. Completed in 1 April 2022.
13 January 2021
Quick facts
| Lead sponsor | University of Rochester |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 25 |
| Start date | 24 April 2020 |
| Primary completion | 13 January 2021 |
| Estimated completion | 1 April 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Remune — full drug profile →
- EXCAP©®
Conditions studied
- Cachexia; Cancer — all drugs for Cachexia; Cancer →
- Weight Loss — all drugs for Weight Loss →
- Lung Cancer — all drugs for Lung Cancer →
- Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →
Sponsor
University of Rochester
Who can join
18 and older, any sex, with Cachexia; Cancer or Weight Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this research study is to determine if the use of a nutritional supplement and exercise improve or worsen cachexia.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cancer cachexia: molecular mechanisms and treatment strategies.
Setiawan T, Sari IN, Wijaya YT, Julianto NM, et al · · 2023 · cited 176× · PMID 37217930 · DOI 10.1186/s13045-023-01454-0 -
Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials.
Fairman CM, Lønbro S, Cardaci TD, VanderVeen BN, et al · · 2022 · cited 28× · PMID 36118249 · DOI 10.1002/rco2.56 -
Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches.
Cencioni C, Trestini I, Piro G, Bria E, et al · · 2022 · cited 24× · PMID 35458104 · DOI 10.3390/nu14081542 -
Cancer cachexia: molecular basis and therapeutic advances.
Tan Y, Xue R, Pan Y, He Z, et al · · 2026 · cited 3× · PMID 41526343 · DOI 10.1038/s41392-025-02331-7 -
Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.
Okamura M, Shirado K, Shirai N, Yagi T, et al · · 2026 · PMID 41884877 · DOI 10.2490/prm.20260012 -
Trends of Decentralized Clinical Trials Using Digital Technology for Decentralization
Sato T, Mizumoto S, Ota M, Shikano M. · · 2022 · DOI 10.2139/ssrn.4243284
Verify or expand the search:
- PubMed search for NCT04131426
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cachexia; Cancer
Currently open trials in the same condition.
- NCT04406662 — Routine Evaluation of People Living With Cancer · recruiting
- NCT03568019 — PET Avidity in Cachexia-Inducing Lung and Gastrointestinal Tumors · active not recruiting
Other University of Rochester trials
Trials by the same sponsor.
- NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
- NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04131426 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rochester
- Last refreshed: 15 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04131426.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing